Biopharma giant Gilead Sciences will shut down its office in Seattle’s Eastlake neighborhood, the company confirmed to ...
Hosted on MSN4h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...
An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback